Myriad Genetics advises prior BRACAnalysis news release be disregarded Myriad Genetics advised that readers should disregard the news release, "Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis" issued April 7 by the company over GlobeNewswire.
Myriad Genetics price target raised to $42 from $34 at Piper Jaffray Piper Jaffray raised its price target for Myriad Genetics shares to $42 to reflect CMS' recent decision to increase BRCA reimbursement. The firm keeps an Overweight rating on the stock.
Myriad Genetics price target raised to $40 from $28 at Mizuho Mizuho raised Myriad's price target to $40 from $28 following the better than expected CMS pricing for BRCA testing. Shares are Neutral rated.